Patients in American hospitals and long-term care facilities face a growing threat from Candida auris, a drug-resistant fungus that has spread rapidly across the country since 2019. The CDC classifies C. auris as an urgent antimicrobial resistance threat, and national case counts have climbed year over year through at least 2021. Outbreaks in COVID-19 specialty units, hemodialysis centers, and long-term acute care hospitals have exposed how quickly the organism moves between patients and facilities, especially when infection-control systems are strained.
Why C. auris case counts keep climbing
The acceleration of C. auris across the United States did not happen in a vacuum. A peer-reviewed study in the Annals of Internal Medicine documented how the fungus expanded sharply from 2019 through 2021, with the COVID-19 pandemic straining the infection-control resources that hospitals rely on to contain resistant organisms. Staffing shortages, increased use of personal protective equipment for respiratory illness, and the sheer volume of critically ill patients diverted attention from fungal surveillance.
That strain showed up in real outbreaks. In Florida during the summer of 2020, C. auris spread through a COVID-19 specialty care unit over the course of July and August, with a joint CDC and state investigation tracing transmission to infection-control lapses tied to pandemic pressures. Months later, between January and April 2021, health officials in Texas and the District of Columbia identified transmission of pan-resistant and echinocandin-resistant strains in healthcare facilities, meaning the fungus had developed resistance to all three major classes of antifungal drugs available for treatment.
The CDC has publicly warned that the fungus is “spreading at an alarming rate,” citing steep increases in clinical infections and colonization across multiple regions in recent years. In a national alert, the agency underscored that C. auris is often resistant to multiple antifungal drugs and can be difficult to identify with standard laboratory methods, which increases the risk that cases go undetected until outbreaks are well underway. That same alert noted that the number of states reporting cases has grown, reflecting both improved detection and genuine geographic expansion.
The hypothesis that mandatory admission screening in high-risk settings like hemodialysis centers could slow the growth of resistant isolates has a logical basis. States that screen patients on entry can identify colonized individuals before they seed an outbreak, while states that rely only on outbreak-triggered contact tracing are, by definition, responding after transmission has already occurred. But testing that hypothesis rigorously requires comparing echinocandin-resistance trends across states with different screening policies, and no published dataset currently breaks out resistance rates by state-level screening mandates in a way that confirms or refutes the idea.
Hemodialysis networks and genomic tracking expose transmission routes
Hemodialysis patients are especially vulnerable. They visit healthcare facilities multiple times per week, share equipment surfaces, and often transfer between hospitals and outpatient dialysis centers. Between 2020 and 2023, containment responses played out in hemodialysis facilities across New Jersey, North Carolina, South Carolina, and Tennessee, according to a CDC report on those containment efforts. State health departments led those responses with notifications, contact screening, and on-site assessments, but the reports also revealed how difficult containment can be once C. auris enters a dialysis network where patients circulate among multiple facilities.
Whole-genome sequencing has become a central tool for tracing how C. auris moves. Updated genomic epidemiologic data published through the CDC’s Emerging Infectious Diseases journal show how sequencing can link cases across states and identify clusters that traditional epidemiology alone would miss. In one analysis, investigators used high-resolution genomic data to connect apparently unrelated clinical isolates, demonstrating how patients transferred between facilities can silently propagate the organism over long distances. That sequencing work has also confirmed the presence of echinocandin-resistant and pan-resistant strains, which narrows treatment options to experimental drugs or combination therapies with limited clinical data behind them.
Those genomic findings dovetail with broader national surveillance. The CDC maintains continuously updated case counts that track the fungus year by year and state by state. According to a recent agency summary, the number of clinical cases rose substantially over a short period, while screening identified a growing pool of colonized patients who could serve as reservoirs for future transmission. The agency has emphasized that both clinical infections and asymptomatic colonization must be addressed to slow the spread, because colonized individuals can contaminate rooms, equipment, and the hands of healthcare workers even when they do not show signs of illness.
To standardize reporting, the CDC established a 2023 case definition that counts both invasive infections, such as bloodstream infections, and certain non-sterile site isolates that may reflect colonization rather than active disease. That distinction matters because it shapes how large the reported numbers appear and whether a “case” means a patient who is sick or simply carrying the organism. Public dashboards that combine these categories can give the impression of explosive clinical disease, when a portion of the increase reflects more aggressive screening and laboratory testing.
Gaps in screening data and disinfectant standards
Several questions remain open. The most pressing is whether proactive screening policies actually reduce resistance rates over time. The hemodialysis containment reports from four states document what happened after C. auris was detected, but they do not compare outcomes against states with different surveillance approaches. Without that comparison, the case for mandatory admission screening rests on biological plausibility rather than demonstrated results.
Environmental persistence adds another layer of difficulty. C. auris can survive on hospital surfaces for weeks, and standard cleaning agents do not reliably kill it. The EPA maintains a list of registered antimicrobial products effective against the fungus, but the most recent version of that list lacks post-2023 updates tied to newly circulating genetic clades. Hospitals that rely on List P products are working from registrations that predate the most recent genomic surveillance data, leaving infection-prevention teams to extrapolate from older efficacy studies when deciding which disinfectants to deploy in high-risk units.
Genomic analyses suggest that multiple clades of C. auris have established themselves in the United States, and some show different resistance profiles and environmental behaviors. A recent investigation of circulating strains in U.S. healthcare facilities used whole-genome sequencing to map introductions and local spread, revealing that certain lineages have become entrenched in long-term care settings and other lineages are appearing in acute-care hospitals. The authors noted that these patterns complicate control efforts, because infection-prevention strategies optimized for one clade may not fully address the characteristics of another.
Patient-level outcome data, including mortality rates and length of hospital stay, remain aggregated in the published literature. The Annals of Internal Medicine study covers national trends but does not link individual hospital records in a way that would let researchers or the public compare outcomes across facilities. Genomic cluster reports cite state health department notifications but do not release the underlying sequencing files or the distance matrices that epidemiologists use to confirm relatedness between isolates. As a result, clinicians and policymakers must rely on summary statistics and selected outbreak descriptions rather than a unified, patient-level dataset that could clarify which infection-control strategies perform best.
These data gaps have practical consequences. Without clear evidence on the impact of admission screening, facilities face difficult decisions about investing in routine surveillance cultures versus focusing resources on rapid response once a case is identified. Without up-to-date disinfectant standards that reflect the latest clades and resistance patterns, environmental services teams must choose between potentially overusing high-level disinfectants or risking inadequate surface decontamination. And without more granular outcome data, it is hard to quantify the full burden of C. auris on patients and health systems or to evaluate whether new antifungal agents and infection-prevention interventions are making a meaningful difference.
For now, the picture that emerges from national surveillance, outbreak investigations, and genomic studies is one of a resilient, adaptable pathogen exploiting weaknesses in healthcare infrastructure. C. auris spreads efficiently when staffing is thin, when surveillance is limited, and when environmental cleaning is not tailored to its unusual hardiness. Closing the remaining gaps in screening data, disinfectant guidance, and patient-level outcomes will be critical if hospitals, dialysis centers, and long-term care facilities hope to reverse the upward trajectory of this emerging fungal threat.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
